Order:
Disambiguations
Edo Richard [5]Edouard Richard [1]
  1.  37
    On the reconceptualization of Alzheimer’s disease.Maartje Schermer & Edo Richard - 2018 - Bioethics 33 (1):138-145.
    In the hope of future treatments to prevent or slow down the disease, there is a strong movement towards an ever-earlier detection of Alzheimer's disease. In conjunction with scientific developments, this has prompted a reconceptualization of AD, as a slowly progressive pathological process with a long asymptomatic phase. New concepts such as "preclinical" and "prodromal" AD have been introduced, raising a number of conceptual and ethical questions. We evaluate whether these new concepts are theoretically defensible, in light of theories of (...)
    Direct download (2 more)  
     
    Export citation  
     
    Bookmark   11 citations  
  2.  28
    On the personal utility of Alzheimer’s disease-related biomarker testing in the research context.Eline M. Bunnik, Edo Richard, Richard Milne & Maartje H. N. Schermer - 2018 - Journal of Medical Ethics 44 (12):830-834.
    Many healthy volunteers choose to take part in Alzheimer’s disease prevention studies because they want to know whether they will develop dementia—and what they can do to reduce their risk—and are therefore interested in learning the results of AD biomarker tests. Proponents of AD biomarker disclosure often refer to the personal utility of AD biomarkers, claiming that research participants will be able to use AD biomarker information for personal purposes, such as planning ahead or making important life decisions. In this (...)
    Direct download (5 more)  
     
    Export citation  
     
    Bookmark   4 citations  
  3.  17
    Should Doctors Offer Biomarker Testing to Those Afraid to Develop Alzheimer’s Dementia?: Applying the Method of Reflective Equilibrium for a Clinical Dilemma.Marthe Smedinga, Eline M. Bunnik, Edo Richard & Maartje H. N. Schermer - 2022 - Journal of Bioethical Inquiry 19 (2):287-297.
    An increasing number of people seek medical attention for mild cognitive symptoms at older age, worried that they might develop Alzheimer’s disease. Some clinical practice guidelines suggest offering biomarker testing in such cases, using a brain scan or a lumbar puncture, to improve diagnostic certainty about Alzheimer’s disease and enable an earlier diagnosis. Critics, on the other hand, point out that there is no effective Alzheimer treatment available and argue that biomarker tests lack clinical validity. The debate on the ethical (...)
    Direct download (3 more)  
     
    Export citation  
     
    Bookmark   1 citation  
  4.  14
    Selecting the target population for new Alzheimer drugs: challenges and expectations.Edo Richard - 2021 - Journal of Medical Ethics 47 (9):615-616.
    The Alzheimer field is in desperate need for an effective treatment. After decades of research, the available drugs treat only symptoms, and even their effectiveness is disputed. Because brain changes precede the clinical symptoms by years to decades, disease-modifying treatments should probably be started early, when the first symptoms occur—or even before. But how to determine who to treat? In this issue, Erik Gustavsson c.s. approach this question by addressing the benefits, harms and ethical issues encountered when using different modes (...)
    Direct download (3 more)  
     
    Export citation  
     
    Bookmark   1 citation  
  5.  3
    Ernest Renan, penseur traditionaliste?Edouard Richard - 1996 - Aix-en-Provence: Presses universitaires d'Aix-Marseilles.
    No categories
    Direct download  
     
    Export citation  
     
    Bookmark  
  6.  9
    Correction to: Should Doctors Offer Biomarker Testing to Those Afraid to Develop Alzheimer’s Dementia?Marthe Smedinga, Eline M. Bunnik, Edo Richard & Maartje H. N. Schermer - 2022 - Journal of Bioethical Inquiry 19 (2):299-299.
    Direct download (3 more)  
     
    Export citation  
     
    Bookmark